Funders › AZ › Ben and Catherine Ivy Foundation › 2020
Grants paid by Ben and Catherine Ivy Foundation, tax year 2020
EIN 27-3322123 · Scottsdale, AZ · Form 990-PF, Part XV · NTEE T20
In tax year 2020, Ben and Catherine Ivy Foundation (EIN 27-3322123) reported 10 grants paid totaling $13,508,952. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2020
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2020 | Az Corona Virus Relief Fund Phoenix, AZ | U | $5,000,000 | paid | DIRECT COSTS FOR PERSONAL PROTECTION EQUIPMENT AND MASKS FOR ARIZONA HOSPITALS. | 202242639349100714 |
| 2020 | Neuro Trials LLC Phoenix, AZ | U | $5,000,000 | paid | BUILDING EXPANSION. | 202242639349100714 |
| 2020 | Neurotrials LLC Phoenix, AZ | U | $2,995,000 | paid | ESTABLISH A PHOENIX-BASED CENTER FOR GLIOBLASTOMA DRUG DISCOVERY (THE IVY BRAIN TUMOR RESEARCH CENTER) EMPHASIZING INDUSTRY -PARTNERED DRUG DEVELOPMENT PAIRED WITH A LARGE PORTFOLIO OF PHASE 0/II TRIALS AND RANDOMIZED PHASE II TRIALS. | 202242639349100714 |
| 2020 | University of Tx Md Anderson Cancer Houston, TX | U | $300,000 | paid | (YEAR 1 OF 2) AMY HEIMBERGER MD - THE USE OF STAT 3 INHIBITION IN COMBINATION WITH RADIATION TO INDUCE ANTIGEN PRESENTING CELL-T CELL IMMUNOLOGICAL SYNAPSES AND SUBSEQUENT T CELL ACTIVATION IN THE GLIOMA MICROENVIRONMENT. | 202242639349100714 |
| 2020 | Mayo Clinic Jacksonville Jacksonville, FL | U | $300,000 | paid | (YEAR 1 OF 2) DR ROSENFELD - DEVELOPMENT OF A TRANSCRIPTOMICALLY-GUIDED THERAPEUTIC STRATEGY THAT COMBINES TARGETED THERAPIES THAT BOTH EFFECTIVELY TREAT GLIOBLASTOMA AND PREVENT THE EMERGENCE OF TREATMENT RESISTANCE. | 202242639349100714 |
| 2020 | City of Hope Medical Center Duarte, CA | U | $300,000 | paid | RENEE POWER(EMERGING LEADER AWARD) ADVANCING IL13RA2-CAR T THERAPY. | 202242639349100714 |
| 2020 | Society of St Vincent de Paul Phoenix, AZ | C | $250,000 | paid | CENTER FOR FAMILY WELLNESS ESTABLISHED TO FOCUS ON THE PREVENTION AND MANAGEMENT OF CHRONIC DISEASES THROUGH NUTRITION, PHYSICAL ACTIVITY AND OVERALL WELLNESS. ITS CULTURALLY GROUNDED BILINGUAL EDUCATION PROGRAMS ENCOURAGE THE WHOLE FAMILY TO PARTICIPATE. | 202242639349100714 |
| 2020 | Emory University Atlanta, GA | U | $250,000 | paid | (YEAR 1 OF 2)DR RENEE READ EMERGING LEADER AWARD - USING PRE-CLINICAL EXPERIMENTAL MODELS TO IDENTIFY BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSE TO AN FDA-APPROVED LIPOSOMAL FORMULATION OF VERTEPORFIN. | 202242639349100714 |
| 2020 | Damon Runyon Cancer Research Fdn New York, NY | U | $100,000 | paid | INVESTIGATION OF A BIOMARKER PHASE 2 STUDY TO EVALUATE TARGETED THERAPY HARBORING SPECIFIC GENETIC ALTERATIONS. | 202242639349100714 |
| 2020 | Swedish Medical Center Seattle, WA | C | -$986,048 | paid | RETURN OF UNUSED FUNDS. | 202242639349100714 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.